On January 8, 2021 Enzychem Lifesciences (KOSDAQ: 183490), reported that Ki Young Sohn, Chief Executive Officer & Chairman, will be presenting a company overview and participating in virtual one-on-one meetings at Biotech Showcase Digital, held January 11-15, 2021 (Press release, Enzychem Lifesciences, JAN 8, 2021, View Source [SID1234573720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At Biotech Showcase 2021, the company will provide a corporate update for its clinical programs, specifically its Phase 2 COVID-19 study and its Phase 2 clinical trial of EC-18 in Chemoradiation-induced Oral Mucositis (CRIOM), which will report results in the first half of this year.

EC-18, the company’s lead investigational candidate, is a novel, first-in-class, immunomodulator, which facilitates the removal of pathogens and danger signals by accelerating the endocytic trafficking of pattern recognition receptors (PRRs).

"2021 will be a significant year for our company, as we will be reporting multiple clinical updates from our pipeline," said Ki Young Sohn, CEO & Chairman of Enzychem Lifesciences. "We look forward to sharing our Phase 2 results in CRIOM and our program in COVID-19 this year, and are in active discussions with a number of strategic partners regarding licensing EC-18 in different indications."

To schedule a meeting with the Enzychem Lifesciences management team at this conference, please visit the Biotech Showcase partnering system or email [email protected].